Skip to main navigation menu Skip to main content Skip to site footer
Español (España) | English
Editorial
Revistas / Journals
Salud, Ciencia y Tecnología Metaverse Basic and Applied Research Data & Metadata Interdisciplinary Rehabilitation Salud, Ciencia y Tecnología - Serie de Conferencias Community and Interculturality in Dialogue Seminars in Medical Writing and Education Health Leadership and Quality of Life Gamification and Augmented Reality Southern perspective / Perspectiva austral
Home
Issue
Current Issue Previous Issues Thematic issues
About
About the Journal Editorial Team Privacy Statement Contact
Author Guidelines
Guidelines for authors Peer Review Process Open Access Policy and Copyright Digital preservation policy Ethical aspects Anti-plagiarism policy Crossmark policy page
Indexing
×
Español (España) | English
Editorial

Salud, Ciencia y Tecnología Metaverse Basic and Applied Research Data & Metadata Interdisciplinary Rehabilitation Salud, Ciencia y Tecnología - Serie de Conferencias Community and Interculturality in Dialogue Seminars in Medical Writing and Education Health Leadership and Quality of Life Gamification and Augmented Reality Southern perspective / Perspectiva austral
Home

Current Issue Previous Issues Thematic issues

About the Journal Editorial Team Privacy Statement Contact

Guidelines for authors Peer Review Process Open Access Policy and Copyright Digital preservation policy Ethical aspects Anti-plagiarism policy Crossmark policy page
Indexing
Original
Published: 2024-06-06
DOI: https://doi.org/10.56294/sctconf2024924

Ocrelizumab and its role in the treatment of multiple sclerosis: A systematic review of the literature

By
María Lucía Campos ,
María Lucía Campos

Facultad de Medicina y Ciencias de la Salud, Universidad Abierta Interamericana. Argentina

Search this author on:

PubMed | Google Scholar
Marcelo Adrian Estrin ,
Marcelo Adrian Estrin

Facultad de Medicina y Ciencias de la Salud, Universidad Abierta Interamericana. Argentina

Search this author on:

PubMed | Google Scholar

Abstract

Introduction: Multiple Sclerosis is an autoimmune, chronic, progressive disease of the central nervous system that affects the myelin sheaths, producing a dysfunction in the nerve impulse, it is one of the main causes of neurological disability in young adults.
Unfortunately, there is no cure for this disease, but there are many treatments to mitigate the outbreaks and progression of the disease. One of the promising drugs is ocrelizumab, a humanized monoclonal antibody against the CD20 antigen of B cells that has recently been approved by the US (Food and Drug Administration) and European (European Medicines Agency) health agencies for the treatment of sclerosis. multiplex (MS) and is the first drug to be marketed for both relapsingremitting MS (RRMS) and primary progressive MS (PPMS). Material and methods: A bibliographic search will be carried out in the different scientific databases, in order to investigate the role of ocrelizumab in the treatment of Multiple Sclerosis. Conclusion: MS is a disease that so far has no cure; however, a wide range of treatments are available that must be chosen according to the patient and his need. Within the vast range of treatment arises monoclonal antibodies that are specialized glycoproteins that are part of the immune system, produced by B cells, with the ability to recognize specific molecules (antigens). They are among the most promising agents for the treatment of MS. The most Used is ocrelizumab.

Keywords:

Multiple Sclerosis,
Illness,
Monoclonal Antibody,
Drug,
Ocrelizumab,

How to Cite

1.
Campos ML, Adrian Estrin MA. Ocrelizumab and its role in the treatment of multiple sclerosis: A systematic review of the literature . Salud, Ciencia y Tecnología - Serie de Conferencias [Internet]. 2024 Jun. 6 [cited 2024 Jul. 27];3:924. Available from: https://conferencias.saludcyt.ar/index.php/sctconf/article/view/924

Copyright Notice

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

Vol. 3 (2024)
See full issue

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.